Thus, this mitochondrial-based gene signature may represent an important new prognostic tool for predicting patient outcomes, in a wide variety of different breast cancer patients, but especially in ER(+) patients treated with hormonal therapies. This evidence concerns the gene ESR1 and breast carcinoma.